Evidence map›Paper›PMID 41783159›Full record

ArticleBiological psychiatry global open science2026

A Novel Polygenic Risk Score Indexing Somatostatin-Expressing Inhibitory Neurons Predicts Somatostatin-Expressing Cell Proportions and Severity of Symptoms in Late-Life Depression.

Fernanda C Dos Santos, Xiaolin Zhou, Kevan P Clifford, Alex Gonzalez Segura, Ayesha S Syeda, Daniel Felsky, Eric J Lenze, Benoit H Mulsant, Shreejoy Tripathy, Etienne Sibille and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biological psychiatry global open science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Fernanda C Dos SantosCampbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada.
Xiaolin ZhouCampbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada.
Kevan P CliffordCampbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada.
Alex Gonzalez SeguraBipolar and Depressive Disorders Unit, Hospital Clínic de Barcelona, Barcelona, Spain.
Ayesha S SyedaCampbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada.
Daniel FelskyCampbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada.
Eric J LenzeDepartment of Psychiatry, Washington University School of Medicine in St. Louis, St. Louis, Missouri.
Benoit H MulsantDepartment of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.
Shreejoy TripathyDepartment of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.
Etienne SibilleCampbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada.
Yuliya S NikolovaCampbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Postmortem studies suggest that somatostatin-expressing (SST+) interneurons are selectively vulnerable in aging and depression. We developed a novel polygenic risk score (PRS) as an in vivo index of interindividual variability of SST-related function and evaluated its association with late-life depression (LLD)-related phenotypes. Methods: We identified genes co-expressed with Results: The SST-PRS was associated with reduced dlPFC SST+ neuron proportion ( Conclusions: The SST-PRS may serve as a novel biomarker of SST+ neuron pathology and of depressive and cognitive symptom burden in LLD.

Indexed as

CognitionDendritic inhibitionGenetic risk scoreLate-life depressionSomatostatinTranscriptome-based polygenic risk score

Identifiers

PMID41783159
PMCPMC12954506

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.